Deferred Tax Assets, Gross of Allogene Therapeutics, Inc. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Allogene Therapeutics, Inc. quarterly Deferred Tax Assets, Gross in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Allogene Therapeutics, Inc. Deferred Tax Assets, Gross for the quarter ending 31 Dec 2025 was $512,928,000, a 13% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Gross, Quarterly (USD)
Deferred Tax Assets, Gross, YoY Quarterly Change (%)

Allogene Therapeutics, Inc. Quarterly Deferred Tax Assets, Gross (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $512,928,000 +$57,104,000 +13% 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q4 2024 $455,824,000 +$38,187,000 +9.1% 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q4 2023 $417,637,000 +$74,371,000 +22% 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q4 2022 $343,266,000 +$119,013,000 +53% 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q4 2021 $224,253,000 +$29,566,000 +15% 31 Dec 2021 10-K 14 Mar 2024 2023 FY
Q4 2020 $194,687,000 +$89,576,000 +85% 31 Dec 2020 10-K/A 14 Mar 2024 2022 FY
Q4 2019 $105,111,000 +$53,307,000 +103% 31 Dec 2019 10-K 23 Feb 2022 2021 FY
Q4 2018 $51,804,000 +$51,804,000 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q4 2017 $0 31 Dec 2017 10-K 27 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.